Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer
Status:
Unknown status
Trial end date:
2019-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the combination of palbociclib with
cetuximab is superior to cetuximab in prolonging overall survival in HPV-negative,
cetuximab-naive patients with recurrent/metastatic squamous cell carcinoma of the head and
neck.